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Summary
Melanoma represents a signiﬁcant malignancy in humans and dogs. Different from genetically engineered
models, sporadic canine melanocytic neoplasms share several characteristics with human disease that could
make dogs a more relevant preclinical model. Canine melanomas rarely arise in sun-exposed sites. Most occur in
the oral cavity, with a subset having intra-epithelial malignant melanocytes mimicking the in situ component of
human mucosal melanoma. The spectrum of canine melanocytic neoplasia includes benign lesions with some
analogy to nevi, as well as invasive primary melanoma, and widespread metastasis. Growing evidence of distinct
subtypes in humans, differing in somatic and predisposing germ-line genetic alterations, cell of origin,
epidemiology, relationship to ultraviolet radiation and progression from benign to malignant tumors, may also
exist in dogs. Canine and human mucosal melanomas appear to harbor BRAF, NRAS, and c-kit mutations
uncommonly, compared with human cutaneous melanomas, although both species share AKT and MAPK
signaling activation. We conclude that there is signiﬁcant overlap in the clinical and histopathological features of
canine and human mucosal melanomas. This represents opportunity to explore canine oral cavity melanoma as a
preclinical model.
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Pigment Cell Melanoma Res. 27; 37–47 PERSPECTIVEIntroduction
Melanoma represents a signiﬁcant health problem with
over 76 690 newly diagnosed cases and over 9480
deaths annually in the United States alone (Howlader
et al., 2013). While there has been signiﬁcant progress in
delineating the underlying genetic alterations and devel-
oping small molecule inhibitors to block key signaling
pathways as well as in harnessing the immune system to
kill melanoma cells, metastatic melanoma remains mostly
an untreatable, ultimately fatal disease. A series of
oncogenic alterations in signaling components primarily
of the MAP-kinase pathway have been identiﬁed. They
affect genes such as BRAF, NRAS, KIT, HRAS, GNAQ,
and GNA11 and, at least early in progression, are found in
a mutually exclusive pattern. The individual mutations are
associated with distinct clinical, histopathological, and
epidemiological features, suggesting that melanocytic
neoplasia is comprised of biologically distinct subtypes
(Broekaert et al., 2010). The subtypes differ in pathoge-
netic factors such as ultraviolet radiation, mutational
processes shaping the cancer genomes, and their cell
of origin (reviewed in Tsao et al., 2012; Whiteman et al.,
2011; D. C. Whiteman and B.C. Bastian, manuscript in
preparation).
These differences indicate that therapeutic or preven-
tative strategies have to be tailored to individual subtypes.
Animal models play a key role in evaluating therapeutic
strategies to treat or prevent cancer. Multiple genetically
engineered mouse models of melanoma have been
developed as preclinical models (reviewed in Damsky
and Bosenberg, 2010; Walker et al., 2011). While most of
these models are valuable to investigate certain aspects
of the disease, they typically lack the genetic complexity
that accompanies naturally evolving cancers in which
single cells may acquire mutations and undergo waves of
clonal expansion to ﬁnally reach a fully evolved malignant
state. In particular, animal models that demonstrate the
entire spectrum of a cancer reaching from benign
neoplasms, primary tumors, and metastases are rare.
Furthermore, most of the contemporary melanoma mod-
els are driven by constitutive activation of BRAF and
NRAS.
Melanocytic neoplasms occur sporadically in many
animals and are particularly frequent in certain breeds of
horses, pigs, and dogs (Goldschmidt and Hendrick, 2002).
In dogs, melanomas are most commonly observed in
Scottish terrier, poodle, golden retriever, dachshund,
cocker spaniel, miniature poodle, Chow Chow, Gordon
setter, and Anatolian Sheepdog breeds, although the true
incidence in individual breeds of dogs is poorly estab-
lished (Bergman et al., 2013). Fatal melanomas in dogs
typically originate from the oral cavity and acral (foot pads
and nail apparatus) sites. They occasionally occur in the
hair-bearing skin, but with much less frequency (Golds-
chmidt and Hendrick, 2002). While the pathogenesis of
canine melanomas is not known, the anatomic distribu-
tion suggests that ultraviolet radiation is not a causative
factor. Similar to human melanocytic neoplasms, the
unequivocal differentiation of benign and malignant
lesions is not always possible.
The noteworthy presence of a frequent lentiginous
intra-epithelial component in canine melanomas, a feature
documented to precede invasive melanomas in humans
that subsequently spread to regional lymph nodes and
eventually to visceral sites, implicates a similar progres-
sion cascade in the dog. In fact, canine oral cavity
melanomas mimic the evolution and clinical progression
of the human disease originating from several mucosal
sites, having similar propensity for invasion and dissem-
ination (Bergman et al., 2013; Piliang, 2011; Prasad et al.,
2004). Additionally, as their human counterparts, canine
melanomas are resistant to chemotherapy and radiation
therapy (Bergman and Wolchok, 2008).
Genetic alterations in canine malignant melanomas
from mucosal or acral sites have not been fully delin-
eated. Activating mutations in BRAF exon 15 are not
found (Fowles et al., 2013; Shelly et al., 2005), similar to
human mucosal melanoma (Maldonado et al., 2003).
Activating mutations of NRAS and c-kit appear to be
absent in canine mucosal melanoma (Chu et al., 2012;
Fowles et al., 2013; Murakami et al., 2011), in contrast to
human mucosal melanoma where these genes are
mutated in 15% of tumors (Curtin et al., 2006).
Apparent commonalities in the clinical and histopatho-
logical features of mucosal melanoma in dogs and
humans raised the possibility that investigational studies
in dogs could lead to insight into the human condition.
Therefore, we assembled a panel of oncologists, pathol-
ogists, and researchers with expertise in melanocytic
neoplasia in dogs and humans to examine similarities
between the disease spectra and how such could be
leveraged to accelerate treatment in both species. Sev-
eral previous studies have explored clinical trials in canine
cancer as a preclinical model to inform the design of
clinical trials in humans (Gordon et al., 2009; Paoloni and
Vail, 2013; Rusk et al., 2006). Similarly, naturally occurring
non-neoplastic diseases in dogs have also yielded infor-
mation relevant to human diseases (Grall et al., 2012;
Shearin and Ostrander, 2010).
Naturally occurring canine melanoma
model for human disease
Basis for consensus
Physician and veterinary pathologists (Table S1) com-
pared histopathological features of 28 human and 139
canine melanoma specimens (Table 1). Melanomas,
contributed by 11 medical and veterinary institutions
representing national treatment centers, were obtained
with appropriate consent and according to institutional
review. Anonymized patient information was reviewed as
available. Canine melanoma specimens were predomi-
nantly from mucosal sites, but included melanomas from
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with both human mucosal and cutaneous melanomas,
including features illustrated within web-based and other
atlases [e.g. www.skinpathology.org/].
No well-recognized classiﬁcation scheme exists for
mucosal melanomas from either species; therefore, eval-
uation included review of melanoma features previously
documented (Goldschmidt and Hendrick, 2002; Patel
et al., 2002; Pﬁster et al., 2012; Prasad et al., 2004;
Smedley et al., 2011b). The salient histopathological fea-
tures of mucosal melanoma were tabulated for both
species (Table S2). Near universal concordance of these
features was observed between canine and human mel-
anoma (Table S2). Analogous architectural features impor-
tant for diagnosing and staging melanoma were noted in
both species (Figure 1). As recognized for cutaneous
melanomas, both human and canine mucosal melanomas
included the range of epithelioid, spindloid, mixed epithe-
lioid/spindloid, or small round blue cell melanocyte mor-
phologies.Somedogspecimensincludedalentiginous-like
growth pattern within stratiﬁed squamous mucosal epi-
thelium and a signiﬁcant radial growth phase involving
mucosal epithelium ﬂanking the vertical growth phase
(Figure 2). By the time of clinical recognition, mucosal
melanomas are typically advanced with considerable local
invasion, ulceration, focal necrosis, and even metastasis,
particularly in the dog. In both species, there was consid-
erable pleomorphism with signiﬁcant variation in cell and
nuclearsize,shape,andpresenceofnucleoli(FigureS1and
Table S2). Given the substantial difference in incidence
between various anatomic sites, the board chose not to
compare frequencies of all features.
Overlapping histopathological features were also noted
for dog and human acral and cutaneous melanomas. Less
than 20% of all cutaneous melanocytic neoplasms in
dogs are malignant, most of the rest being benign canine
melanocytomas (Goldschmidt and Hendrick, 2002). Suf-
ﬁcient numbers of canine cutaneous and acral malignant
melanomas were not available for this study for histo-
pathological comparison. They are comparatively rare and
therefore more difﬁcult to enroll in clinical trials stratiﬁed
by subtype.
Both dog and human malignant melanomas exhibited a
wide range of melanin pigmentation, from intense
pigmentation obscuring cellular detail to no microscopi-
cally detectable melanin (Figure 1 and Figure S1). Intense
pigmentation was more frequently seen in canine mela-
noma. Immunohistochemical (IHC) evaluation of melano-
cytic differentiation (melan-A, PNL2, and TRP2) was
performed on 30 amelanotic and on 78 pigmented canine
(Table S3) and human melanomas. Directly concordant
comparisons of phenotypic differentiation by immunohis-
tochemistry (IHC) are limited by the fact that some
antibodies commonly used to phenotype human mela-
noma specimens are not sufﬁciently reactive for dog, or
lack speciﬁcity for differential diagnosis (eg, S100,
HMB45) (Smedley et al., 2011a). Nineteen of 30 canine
amelanotic tumors lacked labeling with any of the
melanocyte differentiation antibodies (Table S3). As the
diagnosis of melanoma could not be deﬁnitively con-
ﬁrmed in this subset of tumors, they were excluded from
further evaluation in this study by the board. These likely
represent multiple tumor types as dogs experience a
variety of oral cavity mesenchymal tumors requiring
differential diagnosis, but may also include a subset of
amelanotic melanomas failing to immunoreact by IHC.
Human and dog oral/mucosal melanomas have a poor
prognosis, even with limited extent of primary tumor
burden (Goldschmidt and Hendrick, 2002; Prasad et al.,
2004). However, the board discussed the existence of a
category with infrequent cancer-associated mortality,
having previously described characteristics in dogs
(Esplin, 2008), which share features with blue nevi in
humans (Buchner and Hansen, 1987). In contrast to most
canine melanomas (Smedley et al., 2011b), these melan-
ocytic neoplasms have limited size (generally < 2c mi n
diameter), are often intensely pigmented, lack signiﬁcant
cellular atypia, have infrequent mitotic ﬁgures (absent in
56/71 neoplasms), and are rarely ulcerated (< 15% having
only minor ulceration). Such melanocytic neoplasms with
low malignant potential may represent up to 10% of
mucosal melanocytic tumors in dogs and must be
recognized for appropriate clinical management. Addition-
ally, these site-relevant melanocytic neoplasms with low
malignant potential are useful, once excised and diag-
nosed, for contrast in molecular assays of primary canine
melanomas (see below). The relationship between these
oral melanocytic neoplasms with low malignant potential
and benign cutaneous melanocytic lesions in the human,
as well as various subtypes of human melanocytic nevi,
requires additional evaluation.
Table 1. Specimens obtained for comparative melanoma tumor
board review
Human Dog
Anatomic site
Oral/lip 15 130
a
Skin 0 17
b
AUS
c 34
d 11
Other mucosal
e 13 0
aNineteen canine amelanotic oral sarcomas were excluded from
further study based upon the absence of melanocyte differentiation
marker expression by IHC (see Table S2). Twenty-seven of 111 oral
melanomas were considered low malignant potential (see narrative).
An additional 44 low malignant potential melanocytic neoplasms
were studied by a board subpanel.
bIncludes 11 benign cutaneous melanocytomas.
cAcral/ungual/scrotal cutaneous sites.
dThese represent additional melanoma patient specimens, including
acral sites, available for comparison.
eAnorectal, vulvovaginal, gall bladder, sinonasal, and esophagus.
Board participants agreed dogs have rare nasal and anorectal
melanoma.
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Sporadic canine oral melanoma preclinical modelLimited access to specimens from surgical excisions of
dog tumors was a major limiting factor for our histopath-
ological comparison of the complexity of dog and human
melanomas. Many samples were obtained from tissue-
banked specimens, representing only portions of the
tumor rather than the entire specimen. In some
instances, these tumors lacked a contiguous mucosal
component due to ulceration and/or having been subdi-
vided to provide for preservation of multiple specimen
types within the biorepository. Either circumstance com-
promised evaluation of the in situ or radial growth
components. Only a limited number of specimens,
mostly obtained from board members’ surgical pathology
practices, provided an opportunity for a more compre-
hensive histopathological analysis. These limitations pre-
cluded us from assessing the relative frequency of the
presence of a notable in situ or radial growth in more of
the canine cases. This is relevant for evaluating differen-
tiation and potential behavior, particularly of amelanotic
tumors. While access to biobanked canine accessions
provided the board with a readily available national tissue
source for study, complexity of tumor sampling of
biobanked specimens used for histopathology compari-
sons accentuated the difﬁculty in considering lateral as
well as vertical extent of patient disease. Consideration of
such circumstances is important when developing biore-
positories and designing comparative pathology studies.
Activation of key oncogenic signaling pathways was
assessed by IHC using tissue microarrays (TMA) of
primary canine melanomas. Expression levels of
p-AKT
Ser473, KIT, and p-ERK1/2 varied signiﬁcantly, and
no correlation with disease-speciﬁc survival was found
(Figure 3, and Table S4). Phosphorylation of AKT was
evident in all 44 (100%) melanomas on the TMA, although
AB
CD
EF
GH
Figure 1. Similarities between
histopathological features of mucosal
melanomas in dogs and humans.
Photomicrographs of representative human
(left side column A, C, E, G) and dog (right
side column B, D, F, H) melanomas are
shown. (A, B) Ulceration in amelanotic
melanomas. (C, D, E, F) Extensive vertical
growth phase with malignant melanocytes
inﬁltrating the proprial/submucosal muscle
and/or collagen bundles. (G, H) Extensive
invasion of lymph node (LN) parenchyma
by metastatic melanoma (*). Hematoxylin
and eosin stain. (A, B, E, F, Bar = 50 lm; C,
D, G, H, Bar = 500 lm).
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labeling (immunolabeling score < 50, see methods).
Phospho-ERK1/2 expression occurred in 34 of 44 (77%)
canine malignant melanomas. Twenty-three of 44 (52%)
melanomas exhibited both phosphorylation of ERK1/2
and moderate (or greater) AKT phosphorylation (≥ 50 AKT
immunolabeling score), a distinction shared with some
human mucosal melanomas (Omholt et al., 2011). Weak
or absent PTEN expression (deﬁned as PTEN immunola-
beling score < 42, see methods) was observed in 21 of 44
(48%) of these (Table S4), a characteristic also seen in
human melanoma (Bogenrieder and Herlyn, 2010; Davies
et al., 2009; Zhou et al., 2000). Presence of diminished
PTEN expression did not correlate with survival in dogs
(P = 0.47). KIT was expressed in 37 of 44 (85%) canine
melanomas, but only a few cells were labeled in 27 of the
37.
The entity classiﬁed as canine oral melanocytic neopla-
sia with low malignant potential was noted to show a
virtual absence of KIT expression, absent to low p-ERK1/2
and p-AKT expression (Table S4), and had similarly low
relative expression of pathway mediators downstream of
PI3K/AKT (eg, mTOR, pS6, eIF4E), in contrast to malig-
nant melanomas (H.T. Michael and R. M. Simpson,
manuscript in preparation). Overall, outcome information
was available for only a limited number of canine patients,
which received a variety of interventions. Although our
evaluations comparing survival in dogs must be consid-
ered preliminary, it is noteworthy that human patient
outcomes are likewise essentially unlinked to activation
status of these signaling pathways (Dai et al., 2005; Oba
et al., 2011; Slipicevic et al., 2005). Extended studies,
also taking into account genetic alterations, are necessary
for more thorough comparison with human melanoma.
Board consensus perspective
Substantial common characteristics exist in canine and
human mucosal melanomas, indicating that the dog could
serve as a model for human mucosal melanoma. Mucosal
melanomas in dogs and humans share clinical and
histopathological commonalities in their clinical course,
and the need for improved therapeutic modalities to
impact the consistently poor therapeutic response of
metastatic or locally unresectable disease. These parallels
provide rationale for the investment needed to explore
dogs with melanoma as a clinical model for human
melanoma. Additionally, although published mutation
analyses of canine melanomas cover limited gene regions
on small numbers of patients and are not conclusive to
date (Table S5), the results suggest that overlapping
genetic causes exist.
Absence of evidence of BRAF mutation in dogs
(Fowles et al., 2013; Shelly et al., 2005) is analogous to
predominantly wild-type status in human mucosal mela-
nomas (Buery et al., 2011; Maldonado et al., 2003). While
approximately 15% of human cases harbor NRAS muta-
tions, they appear to be rare in canine mucosal mela-
noma, with a single cell line exhibiting heterozygosity for
Q61R in exon 2 (Fowles et al., 2013; Mayr et al., 2003;
Murua Escobar et al., 2004). Reports indicate that
expression of KIT (CD117) in canine melanoma varies
A
B
C
Figure 2. Lentiginous-like in situ involvement in mucosal
melanomas by malignant melanocytes in the mucosal epithelium.
Clusters of malignant melanocytes occur in the epithelial stratum
basale and ascend into superﬁcial strata. Photomicrographs of
hematoxylin–eosin-stained (A) human mucosal melanoma and (B)
canine mucosal melanoma. (C) Radial extension of malignant
melanocytes is evident in the intact mucosal epithelium lateral to the
vertical tumor component in some canine melanomas; (same canine
patient as in B). Antimelan-A immunohistochemistry, red chromogen
label, hematoxylin counter stain. Bar = 50 lm.
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exhibiting KIT expression; however, activating c-kit muta-
tions in dogs have yet to be clearly documented (Chu
et al., 2012; Gomes et al., 2012; Murakami et al., 2011;
Newman et al., 2012). The lack of correlation between
KIT expression and the presence of activating c-kit
mutations has also been documented in human mela-
noma (Beadling et al., 2008; Curtin et al., 2006). There is
conﬂicting information regarding association between KIT
expression and survival in dogs (Gomes et al., 2012;
Newman et al., 2012). KIT expression (in the absence of
activating c-kit mutations) is not predictive of clinical
response to KIT inhibitors in humans (Ugurel et al., 2005;
Wyman et al., 2006). Furthermore, the presence of
activation of signaling pathways in many canine melano-
mas is similar to that seen in human melanoma (Bogen-
rieder and Herlyn, 2010; Dai et al., 2005; Fowles et al.,
2013; Garrido and Bastian, 2010; Kent et al., 2009;
Mikhail et al., 2005; Shelly et al., 2005; Slipicevic et al.,
2005). Detection of AKT and MAPK signaling pathway
activation in primary melanomas from otherwise
untreated dogs in this study corroborates ﬁndings from
ﬁve canine melanoma cell lines (Fowles et al., 2013).
Corresponding activation of AKT and MAPK in human and
canine melanomas supports the existence of similar
constitutive signaling, although the activation may be the
consequence of alternative, as yet undiscovered, genetic
alterations in the dog. Thus, canine melanoma may also
prove useful in the discovery of novel driver mutations in
mucosal melanoma. In the interim, exploration of existing
therapies targeting components of the MAPK and PI3K/
AKT pathways could be evaluated in dogs, particularly in
modeling therapeutics for human melanomas lacking
typical BRAF and NRAS mutations.
Currently, deﬁciencies in canine genome sequence
annotation hamper progress in comparing human and
canine melanoma genetics. More thoroughly annotated
versions of dog genome are forthcoming. Similar to
human melanoma (Curtin et al., 2005; Whiteman et al.,
2011), the board anticipates the existence of distinct
melanoma subtypes in the dog, with differing molecular
aberrations linked to histopathological phenotypes and
outcomes. Deﬁning these entities, through correlations of
not only mutations, but also evaluations of chromosomal,
epigenetic, and expression changes between dog and
human melanoma, will be important to future goals for
modeling human melanoma and improving canine cancer
care.
Melanoma clinical trial initiative in dogs
The interdisciplinary synergy exempliﬁed by this board’s
proceedings can serve as a paradigm for fostering a
substantive canine clinical trial initiative for human mel-
anoma. Evaluating and credentialing canine melanoma as
a surrogate clinical (preclinical) model should be devel-
oped with a veterinary and human clinical and basic
science team approach. Canine clinical oncology trials are
possible using existing infrastructure. For example, 20
academic veterinary medical centers are part of a
consortium organized within the National Cancer Insti-
tute’s Comparative Oncology Program. This program
designs and executes clinical trials in dogs with selected
Figure 3. Analysis of quantitative expression intensity for p-AKT, PTEN, p-ERK1/2, and KIT, and disease-speciﬁc survival within a subset of 27
canine melanoma patients with clinical follow-up. Kaplan–Meier survival curves were generated using patient groups deﬁned as above or below
the median expression for each marker (determined by color deconvolution image analysis as immunolabeling scores of brightﬁeld chromogenic
IHC from TMA tissue cores; see also Table S4). Expression of these proteins in this cohort was not signiﬁcantly correlated with survival, as
assessed using Mantel–Cox test (p-AKT, P = 0.90; PTEN, P = 0.14; p-ERK, P = 0.86, and KIT, P = 0.68). Primary melanoma tissue specimens
were surgically collected from dogs at the time of initial diagnosis prior to further treatment.
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ccrod.cancer.gov/conﬂuence/display/CCRCOPWeb/Com-
parative+Oncology+Trials+Consortium].
As melanoma case management relies on pathology
guidance (Ehrhart and Withrow, 2013), developing the
dog model and formulating clinical trials must include
aims to improve understanding of disease pathogenesis
and deﬁne correlative outcomes as a part of evaluating
therapy. In the past, veterinary therapy has often been
pursued in the absence of sufﬁcient evidence of efﬁcacy
(Butler et al., 2013). Comparison between studies has
been hampered by inadequate quality and consistency of
reporting and due to the small numbers of patients
included. Much remains to be learned about melanoma in
animals that can be enhanced by minimizing patients lost
to follow up in a clinical research setting. Advances in
both human and veterinary patient care have been
chronically hindered by lack of sufﬁcient autopsy evalu-
ation in clinical trials to assess disease status and
treatment consequences at end of life. Comprehension
of what is possible, economic issues, and elected
euthanasia based upon prognosis and/or quality of life
contribute to these difﬁculties in veterinary medicine.
Future approaches must address these issues. Conse-
quently, the board discussed strategic planning for clinical
scientiﬁc development of the dog model useful in both
modeling human disease comparisons and canine patient
care, as well as leading to new knowledge on underlying
melanoma pathobiology (Table 2). It is essential that
pathologists partner with clinicians in trial design and
management of patient specimens for diagnosis and
classiﬁcation based upon an amalgam of contextual
clinical, cellular, and molecular genetic features.
Prospectus
As an ideal clinical model for the human disease would
share a common cell of origin, pathogenesis, disease
progression, clinical, and histopathological features and
responses to therapy, we realize such an ideal model is
yet to be identiﬁed for any human disease. Notwithstand-
ing, and in contrast to genetically engineered mouse
models, dogs represent a unique opportunity to investi-
gate certain subtypes of spontaneous melanoma forma-
tion, progression, metastasis, and disease intervention in
a large mammal that sporadically develops melanoma in
an immunocompetent setting, and in an environment that
is largely shared with humans. Advantages gained by
incorporating a surrogate clinical trial perspective include
ability to obtain serial biopsies of tumor tissues during
therapy for pharmacodynamic and pharmacokinetic analy-
sis as well as the capacity to identify and validate
biomarkers and medical imaging applications. It also
encompasses evaluation of safety proﬁles in a species
historically used in pharmaceutical development. Estab-
lished classical standards of therapy are rare in veterinary
oncology; therefore, it is considered acceptable to offer
clients investigational new cancer treatments for na€ ıve
disease in their dogs, rather than to expect failure of
previously tried cancer drugs ﬁrst, with ethical guidelines
being adhered to (Paoloni and Vail, 2013).
Canine clinical trials could inform novel therapeutic
strategies and inﬂuence phase I and II studies for human
melanoma including targeted therapies, administered sin-
gly or in combination, as well as immune-based melanoma
therapeutics, the preclinical evaluation of which is of
particular interest. For example, the existence of recombi-
nant canine CTLA4-Ig, shown previously to induce long-
lived tolerance (Graves et al., 2009), and also to suppress
Th1 cytokines, lymphocyte proliferation, and thyroglobulin
antibody production in experimental autoimmune thyroid-
itis (Choi et al., 2008), could be compared in a variety of
canine mucosal melanoma treatment settings. Similarly,
development ofother canineantibody-based therapeutics,
such as anti-PD-1, would help to pilot optimization of
relevant human therapeutic approaches, providing oppor-
tunity to mechanistically evaluate immune regulation,
tolerance, and all too frequent eventual loss of effect or
activity in tumor immunology. Therapeutic effectiveness
and optimized schedules can be evaluated much more
rapidlyinspontaneousmelanomainanimmunecompetent
setting. The board believes that attaining the true value of
the canine model will necessitate signiﬁcant focus on
appropriate patient stratiﬁcation by further delineating the
deﬁning genetic, histopathological, molecular, and clinical
featuresofthedifferenttypesofmelanocyticneoplasmsin
dogs to accurately identify the subtypes that best match
their counterparts in humans.
Analysis approach and methods
The National Cancer Institute Comparative Melanoma
Tumor Board is a collaboration of diagnostic/investigative
experts representing scientiﬁc and clinical experience
with canine and human melanocytic lesions (Table S1).
Melanomas were acquired from the Canine Comparative
Oncology and Genomics Consortium (CCOGC, Inc.,
Rockville, MD, USA) biospecimen repository [http://
www.ccogc.net/] and from the diagnostic services of
board members (Table 1). The majority of canine mela-
nomas were surgically resected from the oral mucosa
preceding other treatments, as most canine malignant
melanomas originate there. A series of canine well-
differentiated oral melanocytic neoplasms (Esplin, 2008)
was evaluated comparatively.
Histopathology slides were routinely prepared, stained
with hematoxylin and eosin, and optically scanned as
digital image ﬁles with either Aperio (Leica, Vista, CA,
USA) or Nanozoomer whole-slide imagers (Hamamatsu,
Bridgewater, NJ, USA) at 209 resolution (approximately
0.43 lm/pixel) (Barisoni et al., 2013; Webster et al.,
2011). Images were reviewed using Digital Image Hub
(DIH, Slidepath-Leica, Dublin, Ireland). Tumor board mem-
bers reviewed slides individually via web browser, and
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board members participated in multiple telepathology
webinar conferences and in two meetings at the National
Cancer Institute, Bethesda, Maryland, during which the
panel also met with veterinary and human oncologists,
and melanoma basic and clinical scientists [http://
nih-cbstp.nci.nih.gov/resources_pathology/NCIMelanoma
TumorBoard.asp#TumorBoard].
A tissue microarray (TMA) incorporating 44 melanomas
and 8 mucosal melanocytic neoplasms with low malignant
potential was constructed as described (Takikita et al.,
2009). Additional TMA tissues included human melano-
mas and normal dog and human tissues (control). These
were analyzed by immunohistochemistry (IHC) using
three melanocyte differentiation markers to conﬁrm his-
togenesis (Smedley et al., 2011a), and using antibodies to
KIT, PTEN, and phosphorylated forms of AKT, and ERK1/2
(Table S6). IHC was adapted from previous methods
(Custer et al., 2006). Reagents and conditions are pro-
vided in Table S6. Use of known positive and known
Table 2. Consideration for canine melanoma surrogate clinical trial development strategy
a
Elements of
strategy Fundamental action/procedure Constructive consideration
Clinical documentation
Patient data Presentation/history, duration, previous workup,
management
Breed and other background information
useful to generate data on incidence
Gross lesion
documentation
Extent of disease. Description of speciﬁc anatomic
location (not just indication of oral cavity); dimensions
in mm, two axes; ulceration, evidence of dissemination.
Photograph lesion with a ruler if possible
Biopsy Inclusion for diagnostic intent/therapeutic intent
(excisional, incisional); preservation for correlative
molecular analysis.
Consideration of lateral extent as well as
vertical depth of invasion; attention paid to
quality of sampling, preservation, QA, and
utilization
Pathology review Development of features of malignancy for initial
assessment for trial enrollments: differentiation,
proliferation, growth pattern, invasion, and
dissemination, etc. Continue reﬁning prognostic
summation; Inclusion of IHC panel if needed for diagnosis
Incorporate Table 3. Smedley et al. (2011b)
Capture classical features outlined –
Adapt how used initially versus what
becomes useful from adjunct molecular
data and outcomes
Clinical staging/prognosis and monitoring
Imaging for
dissemination
Ultrasound of lymph nodes to detect metastasis
(includes submandibular)
+/ consideration of removal for staging;
alternative consideration ultrasound-guided
ﬁne needle aspirate cytology for staging
CT (MRI) imaging
evaluation
Lung particularly; lymph node; abdomen Consideration of monitoring for brain
involvement; inclusion of cranial imaging
Biopsy Monitoring response to therapy, as appropriate Lymph nodes or other palpable disease is
recommended
Endpoint
assessment
Necropsy examination, with collection of tissue for
research, and documentation of extent of disease/
host response.
Quality-of-life
measures
Assessments of fatigue, cardiac function, mucositis,
altered mentation, serial assessments of metabolic
and hematological toxicity, threshold of toxicity versus response
Harmonized approach for multicenter trials;
similar to Paoloni and Vail (2013)
Client education Informed consent; necropsy education; should include
education on how the initiative intended to beneﬁt
both dogs and humans relies upon evidence obtained
from patient specimens
Necropsy education; emphasis on historical
shortcomings impediment to progress.
Education design beyond pro forma
consent for necropsy
Follow-up Directly with owner/clients and indirectly with primary
care clinician
Genomics Global discovery genomics, proteomics and informatic
methods: develop and apply. Database and clinical
monitoring integration
aStrategic approach for trial design represents an initial outline to be developed further with medical and veterinary oncologists, pathologists, and
basic and clinical melanoma research investigators for use in developing multidisciplinary trials for piloting therapeutics for human melanoma.
Research outcomes are anticipated to produce parallel beneﬁts for canine melanoma patients.
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reactions for all antibodies used in IHC. Immunolabeling
signal was developed using avidin-/biotin-conjugated alka-
line phosphatase, Vector Red chromogen substrate (Vec-
tor Laboratories, Burlingame, CA, USA), with hematoxylin
counterstain. For canine tumors in which melanocytic
markers were negative or equivocal on TMA, IHC was
repeated on whole-tissue sections to rule out sampling/
heterogeneity issues. Human mucosal melanomas were
diagnosticallyconﬁrmedwithinthesubmittinginstitutions.
Digital image ﬁles of IHC-labeled melanoma TMA slides
were used for relative quantitation of cell signal pathway
protein expression from 44 malignant and 8 canine
mucosal melanocytic neoplasms with low malignant
potential. Image analysis was performed using color
deconvolution software (Aperio, Color deconvolution,
version 9, Vista, CA, USA). An individual analysis area
region of interest was created for each patient melanoma
tissue core using manual image segmentation. Areas of
non-speciﬁc/off-target chromogenic labeling were
excluded. Optical density measurements for the red,
green, and blue components of the red chromogen were
obtained on representative tissues using the software to
optimize detection of chromogen (Vector Red) and its
differentiation from melanin pigment. Three ﬁxed-thresh-
old tiers corresponding to mild, moderate, and strong
immunolabeling intensity were independently established
for each marker using the selected optical density color
vectors. Individual color deconvolution channels as well as
intensity-range pseudo-color markup images were
assessed post-processing to conﬁrm appropriate detec-
tion of chromogen, differentiation of the chromogen from
melanin, and accurate classiﬁcation of labeling intensity.
Relative immunolabeling scores ([1 9% mildly labeled
pixel threshold tier] + [2 9% moderately labeled pixel
threshold tier] + [3 9% strongly labeled pixel threshold
tier]) were calculated for each melanoma core using TMA
slides. Maximum weighted immunolabeling score possi-
ble = 300, when all (100%) pixels were strongly immuno-
labeled. Values were rounded to whole numbers.
Assessments furthermore incorporated subjective immu-
nolabeling score thresholds for p-AKT and PTEN intended
to indicate tissue cores with weak expression and/or
labeling of raremalignant cells (< 50 forp-AKT and< 42 for
PTEN, respectively). Quantiﬁed immunolabeling intensity
extent was useful for comparing relative expression/
activation among canine melanomas assayed with a given
marker, but was considered less appropriate for compar-
isons between different markers. Canine patient survival
information was obtained from the CCOGC, Inc., but was
only available for 27 of 44 melanoma specimens [http://
www.ccogc.net/]. In addition to the limited number of
patients with follow-up, we noted comparisons with
patient outcomes in this study involved probe of compar-
ativesignaltransductionproteinexpressionappliedtosize-
limited 1-mm-diameter TMA tumor tissue cores. Thus,
additional studies would be prudent. Graphs and statistical
analyses were performed using Prism software (version
6.00; Graph Pad, San Diego, CA, USA) and Excel (version
12.3.3; Microsoft Corporation, Redmond, WA, USA).
Acknowledgements
This research was supported by the Intramural Research Program,
Center for Cancer Research, National Cancer Institute, Bethesda,
Maryland. Additional funding support was provided by The Animal
Cancer Foundation, Norwalk, Connecticut [www.acfoundation.org/],
and The Canine Comparative Oncology and Genomics Consortium,
Inc., Rockville, Maryland [http://www.ccogc.net/]. NCI Comparative
Melanoma Tumor Board meeting support was provided by the NCI
Center for Cancer Research and The Animal Cancer Foundation. Dr.
B. C. Bastian is supported by awards R01- CA131524, and P01
CA025874. Drs. J. M. Gary and H. T. Michael are currently molecular
pathology fellows in the NIH Comparative Biomedical Scientist
Training Program supported by the National Cancer Institute, in
partnership with Michigan State University, East Lansing (Gary) and
University of Maryland, College Park (Michael). Dr. M. R. Anver
receives support through the National Cancer Institute, National
Institutes of Health, under Contract No. HHSN261200800001E. The
authors thank Christina Mazcko, NCI, for assistance with study
specimens and patient data, and John Hickerson, Kelly Government
Solutions, for logistical support of tumor board study meetings. The
views of the authors and tumor board members are their own, and no
commercial endorsement is attributable to them or their afﬁliations.
References
Barisoni, L., Nast, C.C., Jennette, J.C. et al. (2013). Digital pathology
evaluation in the multicenter Nephrotic Syndrome Study Network
(NEPTUNE). Clin. J. Am. Soc. Nephrol. 8, 1449–1459.
Beadling, C., Jacobson-Dunlop, E., Hodi, F.S. et al. (2008). KIT gene
mutations and copy number in melanoma subtypes. Clin. Cancer
Res. 14, 6821–6828.
Bergman, P., and Wolchok, J. (2008). Of Mice and Men (and Dogs):
development of a xenogeneic DNA vaccine for canine oral
malignant melanoma. Cancer Ther. 6, 817–826.
Bergman, P.J., Kent, M.S., and Farese, J.P. (2013). Melanoma. In
Withrow and MacEwen’s Small Animal Clinical Oncology. S.J.,
Withrow, D.M., Vail, and R.L., Page, eds. (St. Louis, MO: Elsevier/
Saunders), pp. 321–334.
Bogenrieder, T., and Herlyn, M. (2010). The molecular pathology of
cutaneous melanoma. Cancer Biomark. 9, 267–286.
Broekaert, S.M., Roy, R., Okamoto, I. et al. (2010). Genetic and
morphologic features for melanoma classiﬁcation. Pigment Cell
Melanoma Res. 23, 763–770.
Buchner, A., and Hansen, L.S. (1987). Pigmented nevi of the oral
mucosa: a clinicopathologic study of 36 new cases and review of
155 cases from the literature. Part I: a clinicopathologic study of 36
new cases. Oral Surg. Oral Med. Oral Pathol. 63, 566–572.
Buery, R.R., Siar, C.H., Katase, N., Gunduz, M., Lefeuvre, M., Fujii,
M., Inoue, M., Setsu, K., and Nagatsuka, H. (2011). RAS and BRAF
mutation frequency in primary oral mucosal melanoma. Oncol.
Rep. 26, 783–787.
Butler, L.M., Bonnett, B.N., and Page, R.L. (2013). Epidemiology and
the evidence-based medicine approach. In Withrow and MacE-
wen’s Small Animal Clinical Oncology. S.J., Withrow, D.M.,
Vail, and R.L., Page, eds. (St. Louis, MO: Elsevier/Saunders), pp.
68–82.
Choi, E.W., Shin, I.L., Lee, C.W., and Youn, H.Y. (2008). The effect of
gene therapy using CTLA4Ig/silica-nanoparticles on canine exper-
imental autoimmune thyroiditis. J. Gene Med. 10, 795–804.
ª 2013 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd. 45
Sporadic canine oral melanoma preclinical modelChu, P.Y., Pan, S.L., Liu, C.H., Lee, J., Yeh, L.S., and Liao, A.T.
(2012). KIT gene exon 11 mutations in canine malignant melanoma.
Vet. J. 196, 226–230.
Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets
of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135–
2147.
Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic
activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol.
23, 4340–4346.
Custer, M.C., Risinger, J.I., Hoover, S., Simpson, R.M., Patterson, T.,
and Barrett, J.C. (2006). Characterization of an antibody that can
detect the Kai1/CD82 murine metastasis suppressor. Prostate 66,
567–577.
Dai, D.L., Martinka, M., and Li, G. (2005). Prognostic signiﬁcance of
activated Akt expression in melanoma: a clinicopathologic study of
292 cases. J. Clin. Oncol. 23, 1473–1482.
Damsky, W.E., and Bosenberg, M. (2010). Mouse melanoma models
and cell lines. Pigment Cell Melanoma Res. 23, 853–859.
Davies, M.A., Stemke-Hale, K., Lin, E. et al. (2009). Integrated
molecular and clinical analysis of AKT activation in metastatic
melanoma. Clin. Cancer Res. 15, 7538–7546.
Ehrhart, N., and Withrow, S. (2013). Biopsy principles. In Withrow
and MacEwen’s Small Animal Clinical Oncology. S.J., Withrow,
D.M., Vail, and R.L., Page, eds. (St. Louis, MO: Elsevier/Saunders),
pp. 143–148.
Esplin, D.G. (2008). Survival of dogs following surgical excision of
histologically well-differentiated melanocytic neoplasms of the
mucous membranes of the lips and oral cavity. Vet. Pathol. 45,
889–896.
Fowles, J.S., Denton, C.L., and Gustafson, D.L. (2013). Comparative
analysis of MAPK and PI3K/AKT pathway activation and inhibition
in human and canine melanoma. Vet. Comp. Oncol. doi: 10.1111/
vco.12044. [Epub ahead of print].
Garrido, M.C., and Bastian, B.C. (2010). IT as a therapeutic target in
melanoma. J. Invest. Dermatol. 130,2 0 –27.
Goldschmidt, M., and Hendrick, M. (2002). Tumors of the skin and
soft tissues. In Tumors in Domestic Animals. D.J., Meuten, ed.
(Ames, IA: Iowa State Press), pp. 78–84.
Gomes, J., Queiroga, F.L., Prada, J., and Pires, I. (2012). Study of
c-kit immunoexpression in canine cutaneous melanocytic tumors.
Melanoma Res. 22, 195–201.
Gordon, I., Paoloni, M., Mazcko, C., and Khanna, C. (2009). The
Comparative Oncology Trials Consortium: using spontaneously
occurring cancers in dogs to inform the cancer drug development
pathway. PLoS Med. 6, e1000161.
Grall, A., Guaguere, E., Planchais, S. et al. (2012). PNPLA1 mutations
cause autosomal recessive congenital ichthyosis in golden
retriever dogs and humans. Nat. Genet. 44, 140–147.
Graves, S.S., Stone, D., Loretz, C., Peterson, L., McCune, J.S.,
Mielcarek, M., and Storb, R. (2009). Establishment of long-term
tolerance to SRBC in dogs with recombinant canine CTLA4-Ig.
Transplantation 15, 317–322.
Howlader, N., Noone, A.M., Krapcho, M. et al. (eds). (2013). SEER
Cancer Statistics Review 1975–2010. (Bethesda, MD: National
Cancer Institute). http://seer.cancer.gov/csr/1975_2010/, based on
November 2012 SEER data submission, posted to the SEER web
site, 2013.
Kent, M.S., Collins, C.J., and Ye, F. (2009). Activation of the AKT and
mammalian target of rapamycin pathways and the inhibitory
effects of rapamycin on those pathways in canine malignant
melanoma cell lines. Am. J. Vet. Res. 70, 263–269.
Maldonado, J.L., Fridlyand, J., Patel, H., Jain, A.N., Busam, K.,
Kageshita, T., Ono, T., Albertson, D.G., Pinkel, D., and Bastian,
B.C. (2003). Determinants of BRAF mutations in primary melano-
mas. J. Natl Cancer Inst. 95, 1878–1890.
Mayr, B., Schaffner, G., Reiﬁnger, M., Zwetkoff, S., and Prodinger, B.
(2003). N-ras mutations in canine malignant melanomas. Vet. J.
165, 169–171.
Mikhail, M., Velazquez, E., Shapiro, R. et al. (2005). PTEN expression
in melanoma: relationship with patient survival, Bcl-2 expression,
and proliferation. Clin. Cancer Res. 11, 5153–5157.
Murakami, A., Mori, T., Sakai, H., Murakami, M., Yanai, T., Hoshino,
Y., and Maruo, K. (2011). Analysis of KIT expression and KIT exon
11 mutations in canine oral malignant melanomas. Vet. Comp.
Oncol. 9, 219–224.
Murua Escobar, H., Gunther, K., Richter, A., Soller, J.T., Winkler, S.,
Nolte, I., and Bullerdiek, J. (2004). Absence of ras-gene hot-spot
mutations in canine ﬁbrosarcomas and melanomas. Anticancer
Res. 24, 3027–3028.
Newman, S.J., Jankovsky, J.M., Rohrbach, B.W., and Leblanc, A.K.
(2012). C-kit expression in canine mucosal melanomas. Vet. Pathol.
49, 760–765.
Oba, J., Nakahara, T., Abe, T., Hagihara, A., Moroi, Y., and Furue, M.
(2011). Expression of c-Kit, p-ERK and cyclin D1 in malignant
melanoma: an immunohistochemical study and analysis of prog-
nostic value. J. Dermatol. Sci. 62, 116–123.
Omholt, K., Grafstrom, E., Kanter-Lewensohn, L., Hansson, J., and
Ragnarsson-Olding, B.K. (2011). KIT pathway alterations in muco-
sal melanomas of the vulva and other sites. Clin. Cancer Res. 17,
3933–3942.
Paoloni, M., and Vail, D. (2013). Clinical trials and developmental
therapeutics. In Withrow and MacEwen’s Small Animal Clinical
Oncology. S.J., Withrow, D.M., Vail, and R.L., Page, eds. (St.
Louis, MO: Elsevier/Saunders), pp. 293–304.
Patel, S.G., Prasad, M.L., Escrig, M., Singh, B., Shaha, A.R., Kraus,
D.H., Boyle, J.O., Huvos, A.G., Busam, K., and Shah, J.P. (2002).
Primary mucosal malignant melanoma of the head and neck. Head
Neck 24, 247–257.
Pﬁster, D.G., Ang, K.K., Brizel, D.M. et al. (2012). Mucosal mela-
noma of the head and neck. J. Natl. Compr. Canc. Netw. 10, 320–
338.
Piliang, M.P. (2011). Acral lentiginous melanoma. Clin. Lab. Med. 31,
281–288.
Prasad, M.L., Patel, S.G., Huvos, A.G., Shah, J.P., and Busam, K.J.
(2004). Primary mucosal melanoma of the head and neck: a
proposal for microstaging localized, Stage I (lymph node-negative)
tumors. Cancer 100, 1657–1664.
Rusk, A., Mckeegan, E., Haviv, F., Majest, S., Henkin, J., and Khanna,
C. (2006). Preclinical evaluation of antiangiogenic thrombospon-
din-1 peptide mimetics, ABT-526 and ABT-510, in companion
dogs with naturally occurring cancers. Clin. Cancer Res. 12, 7444–
7455.
Shearin, A.L., and Ostrander, E.A. (2010). Leading the way: canine
models of genomics and disease. Dis. Model Mech. 3,2 7 –34.
Shelly, S., Chien, M.B., Yip, B., Kent, M.S., Theon, A.P., Mccallan,
J.L., and London, C.A. (2005). Exon 15 BRAF mutations are
uncommon in canine oral malignant melanomas. Mamm. Genome
16, 211–217.
Slipicevic, A., Holm, R., Nguyen, M.T., Bohler, P.J., Davidson, B., and
Florenes, V.A. (2005). Expression of activated Akt and PTEN in
malignant melanomas: relationship with clinical outcome. Am. J.
Clin. Pathol. 124, 528–536.
Smedley, R.C., Lamoureux, J., Sledge, D.G., and Kiupel, M. (2011a).
Immunohistochemical diagnosis of canine oral amelanotic melan-
ocytic neoplasms. Vet. Pathol. 48,3 2 –40.
Smedley, R.C., Spangler, W.L., Esplin, D.G., Kitchell, B.E., Bergman,
P.J., Ho, H.Y., Bergin, I.L., and Kiupel, M. (2011b). Prognostic
markers for canine melanocytic neoplasms: a comparative review
of the literature and goals for future investigation. Vet. Pathol. 48,
54–72.
46 ª 2013 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.
Simpson et al.Takikita, M., Altekruse, S., Lynch, C.F. et al. (2009). Associations
between selected biomarkers and prognosis in a population-based
pancreatic cancer tissue microarray. Cancer Res. 69, 2950–2955.
Tsao, H., Chin, L., Garraway, L.A., and Fisher, D.E. (2012).
Melanoma: from mutations to medicine. Genes Dev. 26, 1131–
1155.
Ugurel, S., Hildenbrand, R., Zimpfer, A. et al. (2005). Lack of clinical
efﬁcacy of imatinib in metastatic melanoma. Br. J. Cancer 92,
1398–1405.
Walker, G.J., Soyer, H.P., Terzian, T., and Box, N.F. (2011). Modeling
melanoma in mice. Pigment Cell Melanoma Res. 24, 1158–1176.
Webster, J.D., Simpson, E.R., Michalowski, A.M., Hoover, S.B., and
Simpson, R.M. (2011). Quantifying histological features of cancer
biospecimens for biobanking quality assurance using automated
morphometric pattern recognition image analysis algorithms. J.
Biomol. Tech. 22, 108–118.
Whiteman, D.C., Pavan, W.J., and Bastian, B.C. (2011). The mela-
nomas: a synthesis of epidemiological, clinical, histopathological,
genetic, and biological aspects, supporting distinct subtypes,
causal pathways, and cells of origin. Pigment Cell Melanoma
Res. 24, 879–897.
Wyman, K., Atkins, M.B., Prieto, V., Eton, O., McDermott, D.F.,
Hubbard, F., Byrnes, C., Sanders, K., and Sosman, J.A. (2006).
Multicenter phase II trial of high-dose imatinib mesylate in
metastatic melanoma: signiﬁcant toxicity with no clinical efﬁcacy.
Cancer 106, 2005–2011.
Zhou, X.P., Gimm, O., Hampel, H., Niemann, T., Walker, M.J., and
Eng, C. (2000). Epigenetic PTEN silencing in malignant melanomas
without PTEN mutation. Am. J. Pathol. 157, 1123–1128.
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Pleomorphic cytomorphologies of human
(A, C, E) and canine (B, D, F) mucosal melanomas.
Table S1. National Cancer Institute Comparative Mel-
anoma Tumor Board Members.
Table S2. Mucosal melanoma histopathological
features in study patients.
Table S3. Immunohistochemical evidence of melano-
cyte differentiation in canine malignant melanomas.
Table S4. Immunohistochemical labeling scores for
signal transduction pathway molecule expression in
canine melanomas evaluated on tissue microarray.
Table S5. Summary of previous molecular/genetic
ﬁndings in canine melanoma.
Table S6. Canine melanoma immunohistochemistry
reagents and conditions.
ª 2013 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd. 47
Sporadic canine oral melanoma preclinical model